Literature DB >> 11058206

Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients.

M Avendaño1, R S Goldstein.   

Abstract

BACKGROUND: There has been a steady increase in referrals of patients with multidrug-resistant tuberculosis (MDR-TB) who are human immunodeficiency virus (HIV) negative. Between 1986 and 1999, 40 patients were admitted to the authors' institution, eight of whom were admitted between January and June 1999. The management of such individuals is difficult. Although they are a clinically and epidemiologically important group of patients, few reports detail their management.
OBJECTIVES: To review the demographics, clinical management and long term outcome of 40 non-HIV-infected individuals with MDR-TB referred to the only specialized TB inpatient service in Ontario. PATIENTS AND METHODS: Clinical hospital records were reviewed.
RESULTS: Twenty-one men and 19 women (mean age 41+/-18 years) were admitted between January 1986 and June 1999 with MDR-TB and negative serology for HIV. Thirty-eight patients (95%) were born outside of Canada. Twenty-six patients (65%) had a history of previous TB. All were symptomatic with productive cough and positive sputum smears for acid-fast bacilli. There was a delay of 4.5 months between the initial diagnosis of TB and the recognition of the presence of MDR-TB. Four patients (10%) had TB resistant to isoniazid and rifampin only. Over 50% of patients had TB with additional resistance to streptomycin, and over 40% had additional resistance to ethambutol. Coexisting resistance was also found in significant numbers for pyrazinamide, ethionamide, para-aminosalicylic acid and cycloserine. Bacteriological conversion was achieved in 34 patients (85%). Six patients underwent surgical resection for localized lung disease. Twenty-four patients completed treatment and have remained free of disease for 33+/-25 months. All five patients (12%) who died had longstanding disease before their referral.
CONCLUSIONS: MDR-TB is most frequently seen among immigrants with a previous history of TB, especially if they come from countries in which TB is highly prevalent. Outcome can be improved by a more timely recognition of MDR-TB.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11058206     DOI: 10.1155/2000/457905

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  11 in total

Review 1.  Dimensions of poverty as risk factors for antimicrobial resistant organisms in Canada: a structured narrative review.

Authors:  Teagan King; Richelle Schindler; Swati Chavda; John Conly
Journal:  Antimicrob Resist Infect Control       Date:  2022-01-24       Impact factor: 4.887

2.  Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients.

Authors:  Sarah K Brode; Robert Varadi; Jane McNamee; Nina Malek; Sharon Stewart; Frances B Jamieson; Monica Avendano
Journal:  Can Respir J       Date:  2014-12-10       Impact factor: 2.409

3.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.

Authors:  Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies
Journal:  Eur Respir J       Date:  2012-10-25       Impact factor: 16.671

4.  Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines.

Authors:  Thelma E Tupasi; Rajesh Gupta; Ma Imelda D Quelapio; Ruth B Orillaza; Nona Rachel Mira; Nellie V Mangubat; Virgil Belen; Nida Arnisto; Lualhati Macalintal; Michael Arabit; Jaime Y Lagahid; Marcos Espinal; Katherine Floyd
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

5.  Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China.

Authors:  Yanni Sun; David Harley; Hassan Vally; Adrian Sleigh
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

Review 6.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

7.  Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Authors:  Mayara L Bastos; Hamidah Hussain; Karin Weyer; Lourdes Garcia-Garcia; Vaira Leimane; Chi Chiu Leung; Masahiro Narita; Jose M Penã; Alfredo Ponce-de-Leon; Kwonjune J Seung; Karen Shean; José Sifuentes-Osornio; Martie Van der Walt; Tjip S Van der Werf; Wing Wai Yew; Dick Menzies
Journal:  Clin Infect Dis       Date:  2014-08-05       Impact factor: 9.079

8.  Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics.

Authors:  Jessica Minion; Victor Gallant; Joyce Wolfe; Frances Jamieson; Richard Long
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

9.  Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.

Authors:  Shama D Ahuja; David Ashkin; Monika Avendano; Rita Banerjee; Melissa Bauer; Jamie N Bayona; Mercedes C Becerra; Andrea Benedetti; Marcos Burgos; Rosella Centis; Eward D Chan; Chen-Yuan Chiang; Helen Cox; Lia D'Ambrosio; Kathy DeRiemer; Nguyen Huy Dung; Donald Enarson; Dennis Falzon; Katherine Flanagan; Jennifer Flood; Maria L Garcia-Garcia; Neel Gandhi; Reuben M Granich; Maria G Hollm-Delgado; Timothy H Holtz; Michael D Iseman; Leah G Jarlsberg; Salmaan Keshavjee; Hye-Ryoun Kim; Won-Jung Koh; Joey Lancaster; Christophe Lange; Wiel C M de Lange; Vaira Leimane; Chi Chiu Leung; Jiehui Li; Dick Menzies; Giovanni B Migliori; Sergey P Mishustin; Carole D Mitnick; Masa Narita; Philly O'Riordan; Madhukar Pai; Domingo Palmero; Seung-kyu Park; Geoffrey Pasvol; Jose Peña; Carlos Pérez-Guzmán; Maria I D Quelapio; Alfredo Ponce-de-Leon; Vija Riekstina; Jerome Robert; Sarah Royce; H Simon Schaaf; Kwonjune J Seung; Lena Shah; Tae Sun Shim; Sonya S Shin; Yuji Shiraishi; José Sifuentes-Osornio; Giovanni Sotgiu; Matthew J Strand; Payam Tabarsi; Thelma E Tupasi; Robert van Altena; Martie Van der Walt; Tjip S Van der Werf; Mario H Vargas; Pirett Viiklepp; Janice Westenhouse; Wing Wai Yew; Jae-Joon Yim
Journal:  PLoS Med       Date:  2012-08-28       Impact factor: 11.069

10.  Comparison of characteristics and mortality in multidrug resistant (MDR) and non-MDR tuberculosis patients in China.

Authors:  Yanni Sun; David Harley; Hassan Vally; Adrian Sleigh
Journal:  BMC Public Health       Date:  2015-10-06       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.